Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
ROE | = | 100 | × | Net income (loss) attributable to Illumina stockholders1 | ÷ | Illumina stockholders’ equity1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2020 | = | 100 | × | ÷ | |||
Dec 29, 2019 | = | 100 | × | ÷ | |||
Dec 30, 2018 | = | 100 | × | ÷ | |||
Dec 31, 2017 | = | 100 | × | ÷ | |||
Jan 1, 2017 | = | 100 | × | ÷ | |||
Jan 3, 2016 | = | 100 | × | ÷ | |||
Dec 28, 2014 | = | 100 | × | ÷ | |||
Dec 29, 2013 | = | 100 | × | ÷ | |||
Dec 30, 2012 | = | 100 | × | ÷ | |||
Jan 1, 2012 | = | 100 | × | ÷ | |||
Jan 2, 2011 | = | 100 | × | ÷ | |||
Jan 3, 2010 | = | 100 | × | ÷ | |||
Dec 28, 2008 | = | 100 | × | ÷ | |||
Dec 30, 2007 | = | 100 | × | ÷ | |||
Dec 31, 2006 | = | 100 | × | ÷ | |||
Jan 1, 2006 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$ in millions
The analysis of the financial data reveals several key trends in the company's profitability, equity growth, and return on equity (ROE) over the examined period.
- Net Income (Loss) Attributable to Illumina Stockholders (US$ in millions)
- The net income figures show considerable variability in the early years, starting with a loss of 21 million USD in 2006, followed by a net gain of 40 million USD in the same year. There was a significant loss of 278 million USD in 2007, after which the company returned to profitability from 2008 onward. From 2008 to 2014, net income experienced a general upward trajectory with some fluctuations, peaking at 353 million USD in 2014. A remarkable increase is observed post-2014, reaching a high of 1,002 million USD in 2019. However, the net income declined to 656 million USD in 2020, indicating some volatility or potential impacts on earnings in the latest period.
- Illumina Stockholders’ Equity (US$ in millions)
- The stockholders’ equity exhibits a consistent growth trend throughout the period. Beginning at 72 million USD in 2006, equity steadily expanded to 849 million USD by 2008. This growth continued over the following years, surpassing 1 billion USD by 2012, and reaching 1.5 billion USD by 2013. After a slight dip in 2014, equity resumed its upward trend, achieving 4.6 billion USD in 2020. This persistent increase suggests ongoing reinvestment, capital raising, or accumulation of retained earnings contributing to the company’s robust financial foundation.
- Return on Equity (ROE, %)
- The ROE started with a negative value of -28.79% in 2006, which aligns with the net loss reported that year. It improved significantly in the subsequent years, fluctuating but generally remaining positive. Notable dips occurred in 2007 (-67.62%) and 2008 (5.95%), reflecting the income volatility observed in those years. From around 2010 onwards, ROE stabilized in a range between approximately 8% and 27%, peaking around 26.41% in 2017. Despite some decline, ROE remained relatively strong through 2020, ending at nearly 14%. This pattern suggests that the company managed to generate consistent returns on equity after overcoming early profitability challenges.
In summary, the company faced early profitability difficulties but demonstrated a marked recovery and growth in net income and equity over the studied timeframe. Its ability to maintain a solid return on equity in later years reflects improving operational efficiency and financial strength. The dip in net income in 2020 amidst continued equity growth and a moderate ROE may warrant further investigation to understand underlying factors impacting recent performance.
Comparison to Competitors
Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2020 | |||||||||||||
Dec 29, 2019 | |||||||||||||
Dec 30, 2018 | |||||||||||||
Dec 31, 2017 | |||||||||||||
Jan 1, 2017 | |||||||||||||
Jan 3, 2016 | |||||||||||||
Dec 28, 2014 | |||||||||||||
Dec 29, 2013 | |||||||||||||
Dec 30, 2012 | |||||||||||||
Jan 1, 2012 | |||||||||||||
Jan 2, 2011 | |||||||||||||
Jan 3, 2010 | |||||||||||||
Dec 28, 2008 | |||||||||||||
Dec 30, 2007 | |||||||||||||
Dec 31, 2006 | |||||||||||||
Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2020 | ||
Dec 29, 2019 | ||
Dec 30, 2018 | ||
Dec 31, 2017 | ||
Jan 1, 2017 | ||
Jan 3, 2016 | ||
Dec 28, 2014 | ||
Dec 29, 2013 | ||
Dec 30, 2012 | ||
Jan 1, 2012 | ||
Jan 2, 2011 | ||
Jan 3, 2010 | ||
Dec 28, 2008 | ||
Dec 30, 2007 | ||
Dec 31, 2006 | ||
Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc. | Health Care | |
---|---|---|
Dec 31, 2020 | ||
Dec 29, 2019 | ||
Dec 30, 2018 | ||
Dec 31, 2017 | ||
Jan 1, 2017 | ||
Jan 3, 2016 | ||
Dec 28, 2014 | ||
Dec 29, 2013 | ||
Dec 30, 2012 | ||
Jan 1, 2012 | ||
Jan 2, 2011 | ||
Jan 3, 2010 | ||
Dec 28, 2008 | ||
Dec 30, 2007 | ||
Dec 31, 2006 | ||
Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).